Triple Threat: EMA Endorses Three First-Time Biosimilars

CHMP Backs Rivals To Eylea/Aflibercept, Tysabri/Natalizumab And RoActemra/Tocilizumab

 
• By David Wallace
Three Red London Buses
Three first-time biosimilar nods have come along at once • Source: Shutterstock

More from Biosimilars

More from Products